ABT
Abbott Laboratories
NYSE · USHealthcareMedical - Devices
$101.72+1.03%
Price as of Jul 20, 2026
ABT financials
Abbott Laboratories financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $44.3B | $42.0B | $40.1B | $43.7B |
| Cost of revenue | $19.7B | $20.6B | $20.1B | $21.3B |
| Gross profit | $24.6B | $21.3B | $20.0B | $22.3B |
| Operating expenses | $16.6B | $14.5B | $13.6B | $14.0B |
| Operating income | $8.0B | $6.8B | $6.4B | $8.4B |
| Net income | $6.5B | $13.4B | $5.7B | $6.9B |
| EBITDA | $11.6B | $10.8B | $10.6B | $11.9B |
| Basic EPS | $3.74 | $7.67 | $3.30 | $3.94 |
| Diluted EPS | $3.72 | $7.64 | $3.27 | $3.91 |
| Balance sheet | ||||
| Cash & equivalents | $8.5B | $7.6B | $6.9B | $9.9B |
| Total assets | $86.7B | $81.4B | $73.2B | $74.4B |
| Total liabilities | $33.9B | $33.5B | $34.4B | $37.5B |
| Stockholders’ equity | $52.1B | $47.7B | $38.6B | $36.7B |
| Total debt | $15.1B | $15.3B | $15.9B | $17.9B |
| Net debt | $6.5B | $7.7B | $9.0B | $8.1B |
| Cash flow | ||||
| Operating cash flow | $9.6B | $8.6B | $7.3B | $9.6B |
| Capital expenditure | -$2.2B | -$2.2B | -$2.2B | -$1.8B |
| Free cash flow | $7.4B | $6.4B | $5.1B | $7.8B |
| Dividends paid | -$4.1B | -$3.8B | -$3.6B | -$3.3B |
| Share repurchases | -$893.0M | -$1.3B | -$1.2B | -$3.8B |